Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Wells Fargo & Co (WFC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Wells Fargo & CoTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Wells Fargo & Co vs State Street SPDR S&P Biotech ETF — how do they compare? Wells Fargo & Co trades at $88.25 (market cap $264.66B), while State Street SPDR S&P Biotech ETF trades at $159. The key difference: Wells Fargo & Co pays a 2.29% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Wells Fargo & Co nearer its low. Which is the better fit depends on your goals.

WFCXBI
Market Cap
$264.66B
Sector
FinancialsBroad Market / Factor
52-Week High
$96.40$164.28
52-Week Low
$73.42$86.92
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Wells Fargo & Co

Wells Fargo (WFC) trades at $87.55, up 0.34% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 12.72, net income margin of 25.97%, and ROE of 13.13%. Recent earnings beat expectations in Q2 2026, and the company is expanding digital services like tokenized deposits. Analyst consensus is mixed but leans positive, with a price target of $97.64.

The outlook for WFC is favorable, driven by earnings growth and strategic innovations, though risks include volatile cash flows and economic sensitivity. Upside potential exists if the company meets future earnings and maintains profitability, but investors should monitor execution and macroeconomic factors.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Wells Fargo & Co

Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.

Read more on WFC

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI